Purolite and Codexis Announce Collaboration to Develop and Market Immobilized Enzymes for Pharmaceutical Market
BALA CYNWYD, Pa. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Purolite Corporation and Codexis, Inc. (NAS: CDXS) today announced a joint collaboration to develop and market immobilized enzymes for the pharmaceutical industry.
Enzymes are immobilized through binding to inert resins, allowing for easier separation from a reaction mixture, and immobilization often allows for the use of these enzymes under different conditions and re-use at a commercial scale. The collaboration will enable Purolite and Codexis to develop immobilized transaminase enzymes for use in the production of pharmaceuticals.
"We have selected Purolite as a partner for immobilization based on their experience with support resins and their ability to supply those resins at every scale," said Dr. Peter Seufer-Wasserthal, Senior Vice President, Pharmaceuticals at Codexis. "Under this new collaboration with Purolite, we will be launching a kit of immobilized transaminases as an extension of our CODEX® Screening Kits. The new immobilized enzyme kits will allow potential customers to quickly assess ideas for biocatalytic processes."
"We are very proud to partner with Codexis," said Dr. Alessandra Basso, Business Manager of the LifeTech™ unit at Purolite. "The successful implementation of these ready-to-use immobilized enzymes for fast screening processes opens the door to new concepts of drug development, where scientists who are unfamiliar with biocatalytic processes can easily apply immobilized enzymes to different screening processes that can speed up new-molecule and API development."
Purolite was founded in 1981 and is a leading manufacturer of ion exchange, catalyst, adsorbent and specialty resins. They have developed the widest platform of resins for enzyme immobilization as part of the LifeTech product portfolio. Headquartered in Bala Cynwyd, Pa., the company has ISO-certified manufacturing facilities in the USA, China, and Romania and operates dedicated R&D centers in the USA, China, Romania, Russia, and the UK. Purolite, the only company focused exclusively on the ion exchange market, has 40 sales offices in more than 30 countries. For more information, see www.purolite.com.
About Codexis, Inc.
Codexis, Inc. engineers enzymes for pharmaceutical, biofuel and chemical production. Codexis' proven technology enables scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development - from research to manufacturing. For more information, see www.codexis.com.
Codexis Forward-Looking Statements
This press release contains forward-looking statements relating to potential launch of immobilized enzyme kits. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and could materially affect actual results. Factors that could materially affect actual results include our dependence on a limited number of products in our pharmaceutical business; potential adverse affects to our business if our customers' pharmaceutical products are not received well in the markets; and our ability to develop and commercialize new products for the pharmaceutical market. Additional factors that could materially affect actual results can be found in Codexis' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 9, 2013, including under the caption "Risk Factors." Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Paul Cox, 212-362-1200
Jemma Connor, +44 161 359 3255
Jacob Brodie, Vice President, 267-255-4829
KEYWORDS: United States North America California Pennsylvania
The article Purolite and Codexis Announce Collaboration to Develop and Market Immobilized Enzymes for Pharmaceutical Market originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.